Bromocriptine is a strong inhibitor of brain nitric oxide synthase: Possible consequences for the origin of its therapeutic effects

FEBS Letters

Volumn 406, Issue 1-2, 1997, Pages 33-36

  Renodon, A ^a   Boucher, J L ^a   Sari, M A ^a   Delaforge, M ^a   Ouazzani, J ^b   Mansuy, D ^a  

^a CNRS   (France)

^b INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES   (France)

Author keywords

Bromocriptine; Migraine; Nitric oxide synthase; Parkinson's disease; Prolactin; Selective inhibitor

Indexed keywords

ARGININE; BROMOCRIPTINE; CALMODULIN; ERGOT ALKALOID; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; SUPEROXIDE;

ANIMAL CELL; ARTICLE; CONCENTRATION RESPONSE; DRUG MECHANISM; ENZYME ACTIVATION; ENZYME INHIBITION; MACROPHAGE; MIGRAINE; MOUSE; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT;

ANIMALS; BRAIN; BROMOCRIPTINE; CATALYSIS; ENZYME INHIBITORS; MICE; MICE, INBRED C3H; NADP; NITRIC OXIDE SYNTHASE; OXIDATION-REDUCTION; RATS; RECOMBINANT PROTEINS;

ANIMALIA;

EID: 0030965759     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-5793(97)00232-9     Document Type: Article

References (33)

1. Parkes, D. (1977) in: Advances in Drug Research (Harper, N.J. and Simmonds, A.B., Eds.), pp. 247-344, Academic Press, New York.
2. Weber, H.P. (1980) in: Ergot Compounds and Brain Function: Neuroendocrine and Neuropsychiatric Aspects (Goldstein, M., Ed.), pp 25-34, Raven Press, New York.
3. Ho K.Y., Thorner M.O. Drugs. 36:1988;67-82.
4. Marzatico F., Cafe C., Taborelli M., Benzi G. Neurochem. Res. 18:1993;1101-1111.
5. Del Pozo E., Varga L., Wyss H., Tolis G., Friesen H., Wenner R., Vetter L., Uettwiler A. J. Clin. Endocrinol. Metab. 39:1974;18-26.
6. Earl C.Q., Prozialeck W.C., Weiss B. Life Sci. 35:1984;525-534.
7. Weiss B., Prozialeck W.C., Wallace T.L. Biochem. Pharmacol. 31:1982;2217-2226.
8. Bruhwyler J., Chleide E., Liégeois J.F., Carreer F. Neurosci. Biobehav. Rev. 17:1993;373-384.
9. Kerwin J.F., Heller J., Heller M. Med. Res. Rev. 14:1994;23-74.
10. Knowles R.G., Moncada S. Biochem. J. 298:1994;249-258.
11. Förstermann U., Gath I., Schwarz P., Closs E.I., Kleinert H. Biochem. Pharmacol. 50:1995;1321-1332.
12. Marletta M.A. Cell. 78:1994;927-930.
13. Pou S., Pou W.S., Bredt D.S., Snyder S.H., Rosen G.M. J. Biol. Chem. 267:1992;24173-24176.
14. Klatt P., Schmidt K., Uray G., Mayer B. J. Biol. Chem. 268:1993;14781-14787.
15. Abu-Soud H., Feldman P.L., Clark P., Stuehr D.J. J. Biol. Chem. 269:1994;32318-32326.
16. Abu-Soud H., Stuehr D.J. Proc. Natl. Acad. Sci. USA. 90:1993;10769-10772.
17. Klatt P., Heinzel B., John M., Kastner M., Böhme E., Mayer B. J. Biol. Chem. 267:1992;11374-11378.
18. Pierri L., Pitman L.H., Rae I.D., Winkler D.A., Andrews P.R. J. Med. Chem. 25:1982;937-942.
19. Sari M.A., Booker S., Jaouen M., Vadon S., Boucher J.L., Pompon D., Mansuy D. Biochemistry. 35:1996;7204-7213.
20. Black S.M., Ortiz de Montellano P.R. DNA Cell Biol. 14:1995;789-794.
21. Green L.C., Wagner D.A., Glogowski J., Skipper P.L., Wishnok J.S., Tannebaum S.R. Anal. Biochem. 126:1982;131-138.
22. Finter N.B. J. Gen. Virol. 5:1969;419-424.
23. Stuehr D.J., Ikeda-Saito M. J. Biol. Chem. 267:1992;20547-20550.
24. Salter M., Knowles R.G., Moncada S. FEBS Lett. 281:1991;145-149.
25. Hu J., Lee J.H., El-Fakahany E.E. Psychopharmacology. 114:1994;161-166.
26. Iwahashi K., Yoneyama H., Ohnishi T., Nakamura K., Miyatake R., Suwaki H., Hosokawa K., Ichikawa Y. Neuropsychobiology. 33:1996;76-79.
27. Pryor W.A., Squadrito G.L. Am. J. Physiol. 268:1995;L699-L722.
28. Smith T.S., Swerdlow R.H., Parker W.D., Bennett J.P. NeuroReport. 5:1994;2598-2600.
29. Olesen J., Thomsen L.L., Iversen H.K. Trends Pharmacol. Sci. 15:1994;149-153.
30. Fozard J.R. Arch. Intern. Pharm. Ther. 329:1995;111-119.
31. Gonzalez M.C., Linares J.D., Santos M., Llorente E. Neurosci. Lett. 203:1996;167-170.
32. Bonavera J.J., Sahu A., Kalra P.S., Kalra S.P. Brain Res. 660:1994;175-179.
33. Duvilanski B.H., Zambruno C., Seilicovitch A., Pisera D., Lasaga M., Diaz M.C., Belova N., Rettori V., McCann S.M. Proc. Natl. Acad. Sci. USA. 92:1995;170-174.